Shift Bioscience
Daniel Ives is an accomplished professional in the field of biological sciences, currently serving as CEO and Founder of Shift Bioscience since May 2017. Prior experience includes a role as CDF at The Francis Crick Institute from July 2013 to April 2016 and a financial analyst internship at Deutsche Bank in July 2008. Daniel Ives holds a Doctor of Philosophy (Ph.D.) in Biological Sciences from the University of Cambridge and a Master of Science (MSci) in Biochemistry from Imperial College London. Educational background also includes attendance at Hills Road Sixth Form College.
This person is not in any teams
This person is not in any offices
Shift Bioscience
Shift Bioscience is unlocking safe rejuvenation with cell simulations. Cellular reprogramming is a powerful biological pathway that can reverse ageing and age-driven diseases in the dish but is not yet safe for clinical use. Our team based in Cambridge UK has pioneered the first high throughput, high accuracy ageing biomarker, which can be leveraged in AI-based cell simulations to identify drug targets for safe rejuvenation.